immunology

Pharma

Biogen lays out $5.6B to acquire Apellis

Biogen is bulking up in immunology—and paving the way for its nephrology future—with an M&A play that adds two ongoing launches to its marketed lineup.

Fraiser Kansteiner Mar 31, 2026 10:32am

Galderma doubles Nemluvio peak sales outlook to $4B-plus

Mar 5, 2026 11:20am

Sanofi inks $1.5B deal for Sino Biopharm's novel asset

Mar 4, 2026 3:00am

AbbVie snaps up device plant amid broader $10B US investment

Jan 12, 2026 9:17am

cost cutting restructuring savings reduce spend

InflaRx charts layoffs, cost cuts to lift lead asset's prospects

Jan 8, 2026 11:03am

An arrow incrementally going up stairs before pointing straight up Blue background

Regeneron, AZ regulatory plans bolstered by phase 3 wins

Nov 7, 2025 2:00pm